Paul Ruff

23.8k total citations · 4 hit papers
155 papers, 8.9k citations indexed

About

Paul Ruff is a scholar working on Oncology, Pathology and Forensic Medicine and Epidemiology. According to data from OpenAlex, Paul Ruff has authored 155 papers receiving a total of 8.9k indexed citations (citations by other indexed papers that have themselves been cited), including 107 papers in Oncology, 28 papers in Pathology and Forensic Medicine and 28 papers in Epidemiology. Recurrent topics in Paul Ruff's work include Colorectal Cancer Treatments and Studies (35 papers), Viral-associated cancers and disorders (26 papers) and Global Cancer Incidence and Screening (22 papers). Paul Ruff is often cited by papers focused on Colorectal Cancer Treatments and Studies (35 papers), Viral-associated cancers and disorders (26 papers) and Global Cancer Incidence and Screening (22 papers). Paul Ruff collaborates with scholars based in South Africa, United States and United Kingdom. Paul Ruff's co-authors include Eric Van Cutsem, G. Bodoky, Geert D’Haens, Anatoly Makhson, Tamás Pintér, Jae Kyung Roh, Michael Schlichting, Erika Hitre, Robert Lim and J. Załuski and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Paul Ruff

151 papers receiving 8.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

2009 2.9k citations Eric Van Cutsem, G. Bodoky et al. profile →
Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

2010 1.4k citations Jean‐Yves Douillard, Salvatore Siena et al. Journal of Clinical Oncology profile →
Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

2012 986 citations Eric Van Cutsem, Josep Tabernero et al. Journal of Clinical Oncology profile →
Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study

2014 339 citations Timothy Price, Marc Peeters et al. profile →

Peers

Countries citing papers authored by Paul Ruff

Since Specialization

Citations

This map shows the geographic impact of Paul Ruff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Ruff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Ruff more than expected).

Fields of papers citing papers by Paul Ruff

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Ruff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Ruff. The network helps show where Paul Ruff may publish in the future.

Co-authorship network of co-authors of Paul Ruff

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Ruff. A scholar is included among the top collaborators of Paul Ruff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Ruff. Paul Ruff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cost‐effectiveness of adjuvant chemotherapy for high‐risk stage II and stage III colon cancer in South Africa 2023 ·Cancer Medicine ·(unknown), (unknown), (unknown), (unknown), (unknown), Paul Ruff, Alfred I. Neugut, Chin Hur	3
2	Effects of Genetic Polymorphisms of Drug Metabolizing Enzymes and co‐Medications on Tamoxifen Metabolism in Black South African Women with Breast Cancer 2023 ·Clinical Pharmacology & Therapeutics ·(unknown), Oluwatosin Ayeni, (unknown), (unknown), Roslyn Thelingwani, Wenlong Carl Chen, (unknown), Daniel S. O’Neil, Alfred I. Neugut, Judith S. Jacobson, Paul Ruff, Herbert Cubasch, Maureen Joffe, Collen Masimirembwa	6
3	The South African breast cancer and HIV outcomes study: Profiling the cancer centres and cohort characteristics, diagnostic pathways, and treatment approaches 2023 ·SHILAP Revista de lepidopterología ·Witness Mapanga, Oluwatosin Ayeni, Wenlong Carl Chen, Judith S. Jacobson, Alfred I. Neugut, Paul Ruff, Herbert Cubasch, Daniel S. O’Neil, (unknown), Sharon Čačala, (unknown), (unknown), Sarah Nietz, (unknown), Tobias Chirwa, Valerie McCormack, Maureen Joffe	1
4	Drivers of disparities in stage at diagnosis among women with breast cancer: South African breast cancers and HIV outcomes cohort 2023 ·PLoS ONE ·Witness Mapanga, Shane A. Norris, Ashleigh Craig, Oluwatosin Ayeni, Wenlong Carl Chen, Judith S. Jacobson, Alfred I. Neugut, Paul Ruff, Herbert Cubasch, Daniel S. O’Neil, Ines Buccimazza, Sharon Čačala, (unknown), (unknown), Sarah Nietz, (unknown), Tobias Chirwa, Valerie McCormack, Maureen Joffe	5
5	Discordance between PAM50 intrinsic subtyping and immunohistochemistry in South African women with breast cancer 2023 ·Breast Cancer Research and Treatment ·Thérèse Dix‐Peek, (unknown), (unknown), Caroline Dickens, Tanya N. Augustine, Herbert Cubasch, Alfred I. Neugut, Judith S. Jacobson, Maureen Joffe, Paul Ruff, Raquel Duarte	7
6	Multimorbidity and overall survival among women with breast cancer: results from the South African Breast Cancer and HIV Outcomes Study 2023 ·Breast Cancer Research ·Oluwatosin Ayeni, Maureen Joffe, Witness Mapanga, Wenlong Carl Chen, Daniel S. O’Neil, (unknown), Sarah Nietz, Ines Buccimazza, Sharon Čačala, (unknown), Judith S. Jacobson, Katherine D. Crew, Alfred I. Neugut, (unknown), Paul Ruff, Herbert Cubasch, Tobias Chirwa, Valerie McCormack, Lisa K. Micklesfield, Shane A. Norris	6
7	Prevalence of Monoclonal Gammopathy of Undetermined Significance in Black South African Men 2022 ·Cancer Epidemiology Biomarkers & Prevention ·(unknown), Maureen Joffe, Moosa Patel, Codruța Chiuzan, (unknown), Paul Ruff, Suzanne Lentzsch, Siyang Leng, Judith S. Jacobson, Timothy R. Rebbeck, Alfred I. Neugut	7
8	Survival of south african women with breast cancer receiving anti-retroviral therapy for HIV 2021 ·The Breast ·(unknown), Sarah Nietz, Herbert Cubasch, Caroline Dickens, Thérèse Dix‐Peek, Maureen Joffe, Alfred I. Neugut, Judith S. Jacobson, Raquel Duarte, Paul Ruff	7
9	Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G 2020 ·Cancers ·Hiroya Taniguchi, Takeharu Yamanaka, Daisuke Sakai, Kei Muro, Kentaro Yamazaki, Susumu Nakata, Hiroyuki Kimura, Paul Ruff, Tae Won Kim, Marc Peeters, Timothy Price	8
10	Adjuvant trastuzumab in early HER2-positive breast cancer: Journeying towards the optimal duration of therapy in South Africa 2020 ·South African Medical Journal ·(unknown), (unknown), (unknown), (unknown), Paul Ruff, Marc Blockman	3
11	Evaluation of Emergent Mutations in Circulating Cell-Free DNA and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Treated with Panitumumab in the ASPECCT Study 2018 ·Clinical Cancer Research ·Marc Peeters, Timothy Price, Michael Boedigheimer, Tae Won Kim, Paul Ruff, Peter Gibbs, Anne Thomas, Gaston Demonty, (unknown), Agnes Ang	32
12	Access to Cancer Therapeutics in Low- and Middle-Income Countries 2016 ·American Society of Clinical Oncology Educational Book ·Paul Ruff, Sana Al‐Sukhun, Charmaine Blanchard, Lawrence N. Shulman	50
13	Breast cancer trends differ by ethnicity: a report from the South African National Cancer Registry (1994–2009) 2016 ·European Journal of Public Health ·Elvira Singh, Maureen Joffe, Herbert Cubasch, Paul Ruff, Shane A. Norris, Pedro T. Pisa	17
14	Evaluation of KRAS, NRAS, and BRAF Mutations in Prime: Panitumumab with FOLFOX4 as First-Line Treatment in Metastatic Colorectal Cancer (MCRC) 2013 ·Annals of Oncology ·Kelly S. Oliner, Jean‐Yves Douillard, Salvatore Siena, Josep Tabernero, Ronald L. Burkes, Mario Barugel, Yves Humblet, G. Bodoky, David Cunningham, Jacek Jassem, Fernando Rivera, Ilona Kocáková, Paul Ruff, (unknown), Martin Šmakal, Richard T. Williams, Alan Rong, Jeffrey S. Wiezorek, Roger Sidhu, Scott D. Patterson	2
15	Time Course of Adverse Events in the Velour Trial 2013 ·Annals of Oncology ·David Ferry, Paul Ruff, Radek Lakomý, Jana Prausová, Guy van Hazel, (unknown), (unknown), (unknown), Eric Van Cutsem, Teresa Macarulla	1
16	Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen breakdown → 2012 ·Journal of Clinical Oncology ·Eric Van Cutsem, Josep Tabernero, Radek Lakomý, Hans Prenen, Jana Prausová, Teresa Macarulla, Paul Ruff, Guy A. Van Hazel, Vladimir Moiseyenko, David Ferry, Joe McKendrick, Jonathan Polikoff, Alexia Tellier, R Castan, Carmen J. Allegra	986
17	Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study breakdown → 2010 ·Journal of Clinical Oncology ·Jean‐Yves Douillard, Salvatore Siena, James T. Cassidy, Josep Tabernero, Ronald L. Burkes, Mario Barugel, Yves Humblet, G. Bodoky, David Cunningham, Jacek Jassem, Fernando Rivera, Ilona Kocáková, Paul Ruff, Maria Błasińska-Morawiec, Martin Šmakal, Jean‐Luc Canon, M. Rother, Kelly S. Oliner, Michael Wolf, Jennifer Gansert	1351
18	Intercondylar fossa of the femur: a novel region for DNA extraction 2006 ·The South African Archaeological Bulletin ·(unknown), (unknown), Paul Ruff, Goran Štrkalj	2
19	Ondansetron Compared with Granisetron in the Prophylaxis of Cisplatin-lnduced Acute Emesis: A Multicentre Double-Blind, Randomised, Parallel-Group Study 1994 ·Oncology ·Paul Ruff, W. Paska, L. Goedhals, (unknown), A. Riviére, Daniel Vorobiof, Boaz Bloch, Alison Jones, (unknown), R. Brunet, (unknown), (unknown), B. McQuade	90
20	Invasive Pulmonary Aspergillosis Complicating Influenza A Pneumonia in a Previously Healthy Patient 1985 ·CHEST Journal ·Michael Lewis, J Kallenbach, Paul Ruff, (unknown), (unknown), (unknown)	41

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact